Search

Basel headquartered Nouscom is developing cancer vaccines with a platform that enables it to pack a high number of neoantigens into its product candidates
CEO Marina Udier describes how the company is developing an off the shelf product that includes over 200 neoantigens, a personalized...
Sep 25, 2024